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Abstract
Tissue engineering is an exciting and rapidly evolving technology. In this review, we discuss the recent
progress made in the field of urethral reconstruction and consider the clinical implications and
further advancement of these endeavours.
Introduction and context
The urethra serves as a conduit that allows urine to flow
out of the bladder. In this review, we will discuss
the development of tissue engineering to replace excised
male anterior urethra. The anterior urethra represents the
portion of the urethra extending from the external urethral
meatus back to the distal end of the distal sphincter
mechanism. The anterior urethra has a segmental blood
supply with both a proximal and retrograde supply byway
of the dorsal arteries, an important consideration when
applying a living graft in need of sufficient vascular supply
in order to survive. The anterior urethra is lined by a
stratified columnar epithelium.
Tissue-engineered grafts have been used experimentally
to treat disorders ranging from stricture disease to
hypospadias deformity. The term ‘urethral stricture’
generally refers to anterior urethral disease or a scarring
process involving the spongy erectile tissue of the corpus
spongiosum. Urethral stricturing is a consequence of
ischemic spongiofibrosis occurring within the urethra.
Occasionally, a specific cause may be identified,
although the majority of strictures are idiopathic.
Anterior urethral strictures are managed according to
their size and position, commencing with the less
invasive urethral dilatation, urethral stenting, or ure-
throtomy and progressing to anastomotic or substitution
urethroplasty (or both). Tissue-engineered grafts are
required for substitution urethroplasty. The substitution
graft of choice is a full-thickness buccal mucosal graft
because it is easy to harvest, tough, resilient, easy to
handle, and picks up a blood supply very effectively [1].
It has a privileged immunology and fibroblast behaviour
unlike that of skin and has less associated fibrosis.
In patients in whom a greater amount of mucosa needs
to be harvested, labial (lip) and lingual (tongue) mucosa
may also be harvested. The initial results using these are
seen to be transposable to those seen with buccal mucosa
[2-5]. The use of oral grafts is associated with numerous
potential complications. Intraoperative haemorrhage,
postoperative infection, pain and swelling, damage to
salivary ducts, initial limited oral opening, altered
sensation or numbness, scarring, and even deformity
have been reported. However, in a survey of 295 patients,
Barbagli et al. [6] found that 98.4% would undergo the
surgery again despite the risk of complications.
Recent advances
Given the success of oral grafts, tissue-engineered grafts
of the urethra are required only in cases of extensive
stricture disease or in recurrent cases in which a previous
oral graft was used. Therefore, a lot of this work remains
within the realms of preclinical research. Clinicians have
used unseeded and seeded (with cells) matrices in
patients to fashion a new urethra.
el-Kassaby et al. [7] used acellular bladder matrix in nine
patients with a healthy wound bed, with good results
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seen in eight of these patients, whereas in the six patients
deemed to have a poor wound bed, only two had a good
result, suggesting the importance of a healthy wound bed
for use of the acellular bladder matrix graft. Palminteri
et al. [8] used porcine small intestinal submucosa (SIS) as
an acellular urethroplasty matrix, with 94% success in
the short term, and Fiala et al. [9] reported 80% success
rates at medium-term follow-up, whereas Hauser et al.
[10] reported poorer results with acellular SIS grafts.
Acellular grafts do not show promise in patients who
have had failed urethroplasty or have a poor blood
supply.
Given the varying success rates with acellular grafts,
researchers have begun looking at the use of cell-seeded
grafts. Cells obtained from the patient are multiplied in
the laboratory and attached to a suitable matrix to be re-
implanted in the patient. Results from cell-seeded grafts
are awaited with much anticipation. The drawbacks of a
cell-seeded graft are that it requires a period of cell
culture in a cleanroom laboratory and that at present it is
not suitable as an ‘off the shelf’ product. There are also
cost and time implications. However, the cellular
composition and mechanical properties of cell-seeded
grafts can be approximated better to match urethral
tissue.
Research in our own laboratory first reported on the use
of tissue-engineered buccal mucosa implanted into
humans [11]. We obtained fibroblasts and keratinocytes
from oral mucosal biopsies and cultured these in the
laboratory. The multiplied cells were then attached to a
donor de-epidermised dermis and cultured at an air-fluid
interface to produce a graft for implantation. Cell
culturing techniques allow a virtually infinite amount
of tissue to be produced with just one biopsy and this
tissue may be used at many time points (for instance, if a
repeat procedure was required). This is an important
consideration in the cohort of patients in whom this
technology may be used.
Our pilot clinical study [12] reported on five patients, all
with extensive stricture disease secondary to lichen
sclerosis. From the five patients, three have a patent
urethra (at the time of writing), although all three
required some form of instrumentation. The patients
selected for our study were all complex and the outcomes
must be placed in that context [13]. Moreover, it would
not be ethical to extend this experimental application to
patients with low-burden stricture disease.
Our tissue-engineered grafts were modelled upon buccal
mucosa. The histological similarities may be seen in
Figures 1a and b. We noted that graft contraction and
fibrosis occurred post-implantation and we are currently
looking at techniques to overcome this. Whether the
hyperinflammatory response was due to the lichen
sclerosis or a reaction to the graft matrix is difficult to
ascertain in this group of patients.
Recently, Fossum and Nordenskjold [14] described the
use of autologous urothelial cells obtained from bladder
washings to repair hypospadias deformity in a paediatric
population. The cells were obtained from saline irriga-
tion of the bladder and subsequently were expanded in
the laboratory and finally returned to patients. Results
were encouraging but the authors acknowledge that
more work needs to be carried out to improve the tissue-
engineering techniques. Similarly, Nagele et al. [15]
described a tissue-engineered multilayered urothelium
expanded from bladder washings.
Currently, our work in the laboratory is concentrated on
developing a scaffold that may be used to deliver the
tissue-engineered graft and to reduce contraction and
fibrosis occurring post-implantation. We are also looking
at ways to manufacture sterile scaffold for clinical use
[16]. Feng et al. [17], in a recent study of four different
scaffold materials, assessed mechanical properties and
cell attachment to the various seeded grafts.
Li et al. [18] described cellularisation of acellular bladder
matrix grafts using autologous oral cells. This work has
reached only the in vitro stage using rabbit oral mucosa
cells, but the important finding is the biocompatibility of
bladder acellular matrix with oral mucosa cells. Fu et al.
[19] successfully attached foreskin epidermal cells on an
acellular rabbit bladder matrix and proved this to be
superior in terms of tissue organisation and re-stricturing
compared with an unseeded acellular bladder matrix in a
rabbit model. The same efforts to seed SIS with urothelial
cells and subsequent culture, as attempted by Feil et al.
[20], have been unsuccessful.
Figure 1. Hematoxylin and eosin histological sections of (a) buccal
mucosa and (b) tissue-engineered buccal mucosa
Magnifications, ×40.
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In another avenue of research, Aboushwareb and Atala
[21] described the promising approach of using adult
progenitor stem cells or amniotic/placental stem cells to
create new urethral tissue. However, this approach still
requires much laboratory work. Given the ethical
problems of using embryonic stem cells, much work
has concentrated on obtaining stem cells from many
different tissues, including bone marrow, striated
muscle, fat, skin, and recently testicles.
Implications for clinical practice
The use of acellular bladder mucosa and SIS grafts has
been trialled and has shown results comparable to the
existing use of buccal mucosa in cases with a good
wound bed. In these patients, an oral mucosal graft
is most often sufficient. The necessity for a tissue-
engineered graft depends on whether a reduction in
donor site morbidity is required and on the need for
sufficient donor tissue.
The more pressing need for tissue-engineered grafts is in
the treatment of long complex strictures, where the
requirement for sufficient tissue imposes greater risk of
complication from oral mucosal procedures. These
patients tend to have a poor wound bed and make the
design of the replacement graftmore challenging.With this
in mind, we are still searching for the ideal replacement
graft. To this end, researchers are still in search of the
optimum scaffold, seeded by the correct cells, which
differentiate and repair without fibrosis. Scaffolds provide
structural support and act as an extracellular matrix in
which cell behaviourmay be regulated. Therefore, the ideal
scaffold should promote cell adhesion, proliferation,
migration, and differentiation and have the appropriate
biomechanical properties [22]. The appropriate cell must
survive, proliferate, and differentiate into a cell capable of
allowing the passage of urine without stimulating the
inflammatory pathways to cause stricturing.
In conclusion, the reconstructive strategy used by the
urologist for the treatment of the anterior urethra will
depend on the extent of the disease, underlying
pathology, availability of autologous grafts, and the
underlying wound bed. With further improvements in
seeding acellular matrices, the clinical use of tissue-
engineered materials is set to increase, especially in those
most in need of it.
Abbreviation
SIS, small intestinal submucosa.
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